Circular RNA hsa_circ_0006421 inhibits hepatocellular carcinoma by acting as a ceRNA targeting miR-134-5p/CELF2 pathway

Lv Zhou; Junhao Shi; Junxia Pu; Xiaohao Chen; Yibin Deng

doi:10.54097/23bjg272

Authors

Lv Zhou
Junhao Shi
Junxia Pu
Xiaohao Chen
Yibin Deng

DOI:

https://doi.org/10.54097/23bjg272

Keywords:

Hepatocellular Carcinoma, CELF2, miR-134-5p, hsa_circ_0006421

Abstract

Background: Hepatocellular carcinoma (HCC), ranking as the sixth most prevalent malignancy globally, exhibits substantial clinical burden. Emerging evidence underscores the critical involvement of circular RNAs (circRNAs) in the pathogenesis of various malignancies. While hsa_circ_0006421 has been implicated in gastric cancer progression, its functional significance in HCC remains unexplored. This study investigates the mechanistic role of hsa_circ_0006421 in HCC pathogenesis. Methods: Differentially expressed circRNAs in HCC tissues were identified through integrated bioinformatics analysis of the GSE97332 dataset and high-throughput sequencing of clinical specimens. Functional characterization of hsa_circ_0006421 was performed using in vitro cellular models (HepG2, MHCC97H) and xenograft experiments. Molecular interactions were validated via qRT-PCR, Western blot, and dual-luciferase reporter assays. Results: Clinical analyses revealed significant downregulation of hsa_circ_0006421 in HCC tissues, particularly in patients with cirrhosis history. Functional studies demonstrated that hsa_circ_0006421 overexpression suppressed HCC proliferation, migration, and invasion. Mechanistically, hsa_circ_0006421 functioned as a competitive endogenous RNA by sequestering miR-134-5p, thereby alleviating its inhibitory effect on CELF2 expression. A negative regulatory relationship between miR-134-5p and CELF2 was established, with hsa_circ_0006421 restoration significantly upregulating CELF2 protein levels in HCC cells. Conclusion: Our findings elucidate a novel hsa_circ_0006421/miR-134-5p/CELF2 regulatory axis that suppresses HCC progression, providing potential therapeutic targets for HCC management.

Downloads

Download data is not yet available.

References

[1] HUANG X Y, HUANG Z L, ZHANG P B, et al. CircRNA-100338 Is Associated With mTOR Signaling Pathway and Poor Prognosis in Hepatocellular Carcinoma [J]. Front Oncol, 2019, 9: 392.

[2] FERLAY J, COLOMBET M, SOERJOMATARAM I, et al. Cancer statistics for the year 2020: An overview [J]. Int J Cancer, 2021.

[3] SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.

[4] HUANG Z, ZHOU J K, PENG Y, et al.The role of long noncoding RNAs in hepatocellular carcinoma [J]. Mol Cancer, 2020, 19(1): 77.

[5] ZHOU H, ZHENG X D, LIN C M, et al. Advancement and properties of circular RNAs in prostate cancer: An emerging and compelling frontier for discovering [J]. Int J Biol Sci, 2021, 17(2): 651-669.

[6] LIU C, LI N, DAI G, et al.A narrative review of circular RNAs as potential biomarkers and therapeutic targets for cardiovas-cular diseases [J]. Ann Transl Med, 2021, 9(7): 578.

[7] SHEN H, LIU B, XU J, et al. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer [J]. J Hema-tol Oncol, 2021, 14(1): 134.

[8] SONG T F, XU A L, CHEN X H, et al. Circular RNA circRNA_101996 promoted cervical cancer development by regulating miR-1236-3p/TRIM37 axis[J]. Kaohsiung J Med Sci, 2021, 37(7): 547-561.

[9] ZHENG X, HUANG M, XING L, et al. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer [J]. Mol Cancer, 2020, 19(1): 73.

[10] LI J, MA M, YANG X, et al. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab[J]. Mol Cancer, 2020, 19(1): 142.

[11] XU H, LIU Y, CHENG P, et al. CircRNA_0000392 promotes colorectal cancer progression through the miR-193a-5p/PIK3R3/AKT axis [J]. J Exp Clin Cancer Res, 2020, 39(1): 283.

[12] ZHAO C X, YAN Z X, WEN J J, et al. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma pro-gression via miR-BART19-3p/APC/beta-catenin axis [J]. Mol Cancer, 2021, 20(1): 153.

[13] WANG G, SUN D, LI W, et al. CircRNA_100290 promotes GC cell proliferation and invasion via the miR-29b-3p/ITGA11 axis and is regulated by EIF4A3[J]. Cancer Cell Int, 2021, 21(1): 324.

[14] XU J, JI L, LIANG Y, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1 [J]. Signal Transduct Target Ther, 2020, 5(1): 298.

[15] CAO P, MA B, SUN D, et al. hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR-139-3p/CCL5 axis [J]. Cancer Sci, 2022, 113(2): 634-647.

[16] WU S, YANG J, XU H, et al. Circular RNA circGLIS3 promotes bladder cancer proliferation via the miR-1273f/SKP1/Cyclin D1 axis[J]. Cell Biol Toxicol, 2022, 38(1): 129-146.

[17] FAN H N, ZHAO X Y, LIANG R, et al. CircPTK2 inhibits the tumorigenesis and metastasis of gastric cancer by sponging miR-134-5p and activating CELF2/PTEN signaling [J]. Pathol Res Pract, 2021, 227: 153615.

[18] LIU D, LIU W, CHEN X, et al. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regu-lating miR-520c-3p/methyl-DNA-binding domain protein 2 axis [J]. Clin Transl Med, 2022, 12(1): e662.

[19] LUO Z, LU L, TANG Q, et al. CircCAMSAP1 promotes hepatocellular carcinoma progression through miR-1294/GRAMD1A pathway [J]. J Cell Mol Med, 2021, 25(8): 3793-3802.

[20] ZHANG P F, WEI C Y, HUANG X Y, et al. Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression[J]. Mol Cancer, 2019, 18(1): 105.

[21] WANG Z, LEI X, WU F X. Identifying Cancer-Specific circRNA-RBP Binding Sites Based on Deep Learning[J]. Molecules,2019, 24(22).

[22] ZHENG L, LIANG H, ZHANG Q, et al. circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-beta/Smad signaling [J]. Mol Cancer, 2022, 21(1): 41.

[23] GUO X Y, LIU T T, ZHU W J, et al. CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis[J]. Onco-gene, 2022.

[24] WANG Z, YANG L, WU P, et al. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin[J]. Mol Cancer, 2022, 21(1): 29.

[25] CHEN S, CAO X, ZHANG J, et al. circVAMP3 Drives CAPRIN1 Phase Separation and Inhibits Hepatocellular Carcinoma by Suppressing c-Myc Translation [J]. Adv Sci (Weinh), 2022: e2103817.

[26] ZHANG L, HUANG P, LI Q, et al. miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2 [J]. Mol Ther Nucleic Acids, 2019,18: 627-637.

[27] LIU Y, CHEN X, LIU J, et al. Circular RNA circ_0004277 Inhibits Acute Myeloid Leukemia Progression Through Mi-croRNA-134-5p / Single stranded DNA binding protein 2[J]. Bioengineered, 2022, 13(4): 9662-9673.

[28] LIAO C, CHEN W, WANG J. MicroRNA-20a Regulates Glioma Cell Proliferation, Invasion, and Apoptosis by Targeting CUGBP Elav-Like Family Member 2[J]. World Neurosurg, 2019, 121: e519-e527.

[29] WANG L, LIU Z, LIU L, et al. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis [J]. J Cell Mol Med, 2021, 25(15): 7559-7574.

[30] ZHOU L, XIE X. RNA-binding protein CELF2 inhibits breast cancer cell invasion and angiogenesis by downregulating NFATc1 [J]. Exp Ther Med, 2021, 22(2): 898.

[31] GUO Q, WU Y, GUO X, et al. The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B [J]. Mol Ther Nucleic Acids, 2021, 23: 169-184.

[32] XIE S C, ZHANG J Q, JIANG X L, et al. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma[J]. Cell Death Dis, 2020, 11(8): 676.

[33] WU J Z, JIANG N, LIN J M, et al. STYXL1 promotes malignant progression of hepatocellular carcinoma via downregulating CELF2 through the PI3K/Akt pathway [J]. Eur Rev Med Pharmacol Sci, 2020, 24(6): 2977-2985.